Tobacco Smoking and Mortality in Asia: A Pooled Meta-analysis.
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
01 03 2019
01 03 2019
Historique:
entrez:
30
3
2019
pubmed:
30
3
2019
medline:
26
11
2019
Statut:
epublish
Résumé
Understanding birth cohort-specific tobacco smoking patterns and their association with total and cause-specific mortality is important for projecting future deaths due to tobacco smoking across Asian populations. To assess secular trends of tobacco smoking by countries or regions and birth cohorts and evaluate the consequent mortality in Asian populations. This pooled meta-analysis was based on individual participant data from 20 prospective cohort studies participating in the Asia Cohort Consortium. Between September 1, 2017, and March 31, 2018, a total of 1 002 258 Asian individuals 35 years or older were analyzed using Cox proportional hazards regression analysis and random-effects meta-analysis. The pooled results were presented for mainland China; Japan; Korea, Singapore, and Taiwan; and India. Tobacco use status, age at starting smoking, number of cigarettes smoked per day, and age at quitting smoking. Country or region and birth cohort-specific mortality and the population attributable risk for deaths from all causes and from lung cancer. Of 1 002 258 participants (51.1% women and 48.9% men; mean [SD] age at baseline, 54.6 [10.4] years), 144 366 deaths (9158 deaths from lung cancer) were ascertained during a mean (SD) follow-up of 11.7 (5.3) years. Smoking prevalence for men steadily increased in China and India, whereas it plateaued in Japan and Korea, Singapore, and Taiwan. Among Asian male smokers, the mean age at starting smoking decreased in successive birth cohorts, while the mean number of cigarettes smoked per day increased. These changes were associated with an increasing relative risk of death in association with current smoking in successive birth cohorts of pre-1920, 1920s, and 1930 or later, with hazard ratios for all-cause mortality of 1.26 (95% CI, 1.17-1.37) for the pre-1920 birth cohort, 1.47 (95% CI, 1.35-1.61) for the 1920s birth cohort, and 1.70 (95% CI, 1.57-1.84) for the cohort born in 1930 or later. The hazard ratios for lung cancer mortality were 3.38 (95% CI, 2.25-5.07) for the pre-1920 birth cohort, 4.74 (95% CI, 3.56-6.32) for the 1920s birth cohort, and 4.80 (95% CI, 3.71-6.19) for the cohort born in 1930 or later. Tobacco smoking accounted for 12.5% (95% CI, 8.4%-16.3%) of all-cause mortality in the pre-1920 birth cohort, 21.1% (95% CI, 17.3%-24.9%) of all-cause mortality in the 1920s birth cohort, and 29.3% (95% CI, 26.0%-32.3%) of all-cause mortality for the cohort born in 1930 or later. Tobacco smoking among men accounted for 56.6% (95% CI, 44.7%-66.3%) of lung cancer mortality in the pre-1920 birth cohort, 66.6% (95% CI, 58.3%-73.5%) of lung cancer mortality in the 1920s birth cohort, and 68.4% (95% CI, 61.3%-74.4%) of lung cancer mortality for the cohort born in 1930 or later. For women, tobacco smoking patterns and lung cancer mortality varied substantially by countries and regions. In this study, mortality associated with tobacco smoking continued to increase among Asian men in recent birth cohorts, indicating that tobacco smoking will remain a major public health problem in most Asian countries in the coming decades. Implementing comprehensive tobacco-control programs is warranted to end the tobacco epidemic.
Identifiants
pubmed: 30924901
pii: 2729479
doi: 10.1001/jamanetworkopen.2019.1474
pmc: PMC6450311
doi:
Types de publication
Journal Article
Meta-Analysis
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e191474Subventions
Organisme : NCI NIH HHS
ID : R01 CA043092
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA173640
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA080205
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA182910
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA144034
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA082729
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA053890
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA182876
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
J Epidemiol Community Health. 2017 Feb;71(2):154-161
pubmed: 27660401
Bull World Health Organ. 2013 May 1;91(5):332-40
pubmed: 23678196
BMC Med. 2015 Feb 24;13:38
pubmed: 25857449
Environ Health Perspect. 2014 Sep;122(9):906-11
pubmed: 24911630
N Engl J Med. 2011 Feb 24;364(8):719-29
pubmed: 21345101
BMJ. 1994 Oct 8;309(6959):901-11
pubmed: 7755693
Prev Med. 2006 Feb;42(2):120-7
pubmed: 16271753
Eur J Cancer Prev. 2005 Oct;14(5):477-83
pubmed: 16175053
Int J Cancer. 1995 Jan 17;60(2):190-3
pubmed: 7829214
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
BMJ. 2004 Jun 26;328(7455):1519
pubmed: 15213107
Tob Control. 2014 Jul;23(4):359-68
pubmed: 23596197
Science. 1987 Jan 9;235(4785):217-20
pubmed: 3798109
Nat Rev Cancer. 2009 Sep;9(9):655-64
pubmed: 19693096
Lancet. 2017 May 13;389(10082):1885-1906
pubmed: 28390697
Stat Med. 2017 Feb 28;36(5):855-875
pubmed: 27747915
Lancet. 2015 Oct 10;386(10002):1447-56
pubmed: 26466050
JAMA. 2008 May 7;299(17):2037-47
pubmed: 18460664
PLoS Med. 2014 Apr 22;11(4):e1001631
pubmed: 24756146
Lancet. 2013 Jan 12;381(9861):133-41
pubmed: 23107252
PLoS Med. 2006 Nov;3(11):e442
pubmed: 17132052
JAMA Intern Med. 2017 Jan 1;177(1):87-95
pubmed: 27918784
N Engl J Med. 2013 Jan 24;368(4):351-64
pubmed: 23343064
BMJ. 2012 Oct 25;345:e7093
pubmed: 23100333
Stat Med. 1991 Nov;10(11):1753-73
pubmed: 1845304
N Engl J Med. 2013 Jan 24;368(4):341-50
pubmed: 23343063
PLoS Med. 2008 Sep 30;5(9):e185
pubmed: 18788891